Last reviewed · How we verify
BKM-120 Bevacizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BKM-120 Bevacizumab (BKM-120 Bevacizumab) — Toni Choueiri, MD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BKM-120 Bevacizumab TARGET | BKM-120 Bevacizumab | Toni Choueiri, MD | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BKM-120 Bevacizumab CI watch — RSS
- BKM-120 Bevacizumab CI watch — Atom
- BKM-120 Bevacizumab CI watch — JSON
- BKM-120 Bevacizumab alone — RSS
Cite this brief
Drug Landscape (2026). BKM-120 Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/bkm-120-bevacizumab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab